[시장보고서]세계의 비인간 영장류용 바이러스 벡터 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

세계의 비인간 영장류용 바이러스 벡터 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Viral Vectors for Non-human Primates Market (Vector Type: Adenoviral Vectors, Adeno-associated Vectors, Retroviral Vectors, Lentiviral Vectors, and Other Vectors) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

상품코드 : 1552718

리서치사 : Transparency Market Research

발행일 : 2024년 07월

페이지 정보 : 영문 253 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,059,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,232,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 16,404,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

비인간 영장류용 바이러스 벡터 시장 - 조사 범위

TMR의 조사 보고서 ''비인간 영장류 바이러스 벡터 세계 시장''에 대해서도 조사했습니다. 본 보고서에서는 2024년 기준년, 2034년 예측년으로 2018-2034년 세계의 비인간 영장류용 바이러스 벡터 시장의 수익과 예측을 제공합니다. 또한 2024-2034년 세계 비인간 영장류용 바이러스 벡터 시장의 복합 연간 성장률(CAGR%)도 제공합니다.

이 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서 분석가는 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰를 실시했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 비인간 영장류용 바이러스 벡터 시장을 추찰했습니다.

시장 현황
2023년 시장 규모	1억 4,580만 달러
2034년 시장 규모	4억 2,990만 달러
CAGR	10.5%

본 보고서에서는 세계의 비인간 영장류용 바이러스 벡터 시장 경쟁 구도를 조사했습니다. 세계의 비인간 영장류용 바이러스 벡터 시장에서 사업을 전개하는 주요 기업이 확인되고, 각 기업이 다양한 속성으로 프로파일 되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT 등이 본 보고서에서 소개되고 있는 세계의 비인간 영장류용 바이러스 벡터 시장에 있어서의 기업의 속성입니다.

시장기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2023)
시장 실적 분석
경쟁 스냅샷
기업 프로파일
- Lonza
- Thermo Fisher Scientific Inc
- Revvity
- VectorBuilder Inc.
- Creative Biolabs
- Takara Bio Inc
- MERCK KGaA
- Andelyn Biosciences
- Biovian Oy
- Genezen

JHS

영문 목차

영문목차

Viral Vectors for Non-human Primates Market - Scope of Report

TMR's report on the global viral vectors for non-human primates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global viral vectors for non-human primates market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global viral vectors for non-human primates market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the viral vectors for non-human primates market.

Market Snapshot
Market Value in 2023	US$ 145.8 Mn
Market Value in 2034	US$ 429.9 Mn
CAGR	10.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global viral vectors for non-human primates market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global viral vectors for non-human primates market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global viral vectors for non-human primates market.

The report delves into the competitive landscape of the global viral vectors for non-human primates market. Key players operating in the global viral vectors for non-human primates market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global viral vectors for non-human primates market profiled in this report.

Key Questions Answered in Global viral vectors for non-human primates Market Report:

What is the sales/revenue generated by viral vectors for non-human primates across all regions during the forecast period?
What are the opportunities in the global viral vectors for non-human primates market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Viral Vectors for Non-human Primates Market - Research Objectives and Research Approach

The comprehensive report on the global viral vectors for non-human primates market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global viral vectors for non-human primates market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global viral vectors for non-human primates market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Viral Vectors for Non-human Primates Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, 2020-2034
- 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Recent Advancements in Viral Vector Technology
5.2. Porter's Five Forces Analysis
5.3. List of Leading CROs Offering Non-human Primate based Preclinical Testing Services
5.4. PESTLE Analysis
5.5. Key Industry Events (Product Approvals, Partnerships, and Collaborations)

6. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Vector Type

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Vector Type, 2020-2034
- 6.3.1. Adenoviral Vectors
- 6.3.2. Adeno-associated Vectors
- 6.3.3. Retroviral Vectors
- 6.3.4. Lentiviral Vectors
- 6.3.5. Others
6.4. Market Attractiveness By Vector Type

7. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Type of Non-human Primates

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
- 7.3.1. Marmosets
- 7.3.2. Rhesus macaques
- 7.3.3. Cynomolgus monkey
- 7.3.4. Others
7.4. Market Attractiveness By Type of Non-human Primates

8. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Application

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Application, 2020-2034
- 8.3.1. Gene Therapy
- 8.3.2. Vaccine Research
8.4. Market Attractiveness By Application

9. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Therapeutic Area

9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Therapeutic Area, 2020-2034
- 9.3.1. Genetic Disorders
- 9.3.2. Infectious Diseases
- 9.3.3. Oncological Disorders
- 9.3.4. Others
9.4. Market Attractiveness By Therapeutic Area

10. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By End-user

10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By End-user, 2020-2034
- 10.3.1. Pharmaceutical and Biotechnology Companies
- 10.3.2. Academic and Research Institutions
10.4. Market Attractiveness By End-user

11. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Region

11.1. Key Findings
11.2. Market Value Forecast By Region
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
11.3. Market Attractiveness By Region

12. North America Viral Vectors for Non-human Primates Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Vector Type, 2020-2034
- 12.2.1. Adenoviral Vectors
- 12.2.2. Adeno-associated Vectors
- 12.2.3. Retroviral Vectors
- 12.2.4. Lentiviral Vectors
- 12.2.5. Others
12.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
- 12.3.1. Marmosets
- 12.3.2. Rhesus macaques
- 12.3.3. Cynomolgus monkey
- 12.3.4. Others
12.4. Market Value Forecast By Application, 2020-2034
- 12.4.1. Gene Therapy
- 12.4.2. Vaccine Research
12.5. Market Value Forecast By Therapeutic Area, 2020-2034
- 12.5.1. Genetic Disorders
- 12.5.2. Infectious Diseases
- 12.5.3. Oncological Disorders
- 12.5.4. Others
12.6. Market Value Forecast By End-user, 2020-2034
- 12.6.1. Pharmaceutical and Biotechnology Companies
- 12.6.2. Academic and Research Institutions
12.7. Market Value Forecast By Country, 2020-2034
- 12.7.1. U.S.
- 12.7.2. Canada
12.8. Market Attractiveness Analysis
- 12.8.1. By Vector Type
- 12.8.2. By Type of Non-human Primates
- 12.8.3. By Application
- 12.8.4. By Therapeutic Area
- 12.8.5. By End-user
- 12.8.6. By Country

13. Europe Viral Vectors for Non-human Primates Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Vector Type, 2020-2034
- 13.2.1. Adenoviral Vectors
- 13.2.2. Adeno-associated Vectors
- 13.2.3. Retroviral Vectors
- 13.2.4. Lentiviral Vectors
- 13.2.5. Others
13.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
- 13.3.1. Marmosets
- 13.3.2. Rhesus macaques
- 13.3.3. Cynomolgus monkey
- 13.3.4. Others
13.4. Market Value Forecast By Application, 2020-2034
- 13.4.1. Gene Therapy
- 13.4.2. Vaccine Research
13.5. Market Value Forecast By Therapeutic Area, 2020-2034
- 13.5.1. Genetic Disorders
- 13.5.2. Infectious Diseases
- 13.5.3. Oncological Disorders
- 13.5.4. Others
13.6. Market Value Forecast By End-user, 2020-2034
- 13.6.1. Pharmaceutical and Biotechnology Companies
- 13.6.2. Academic and Research Institutions
13.7. Market Value Forecast By Country, 2020-2034
- 13.7.1. Germany
- 13.7.2. U.K.
- 13.7.3. France
- 13.7.4. Spain
- 13.7.5. Italy
- 13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
- 13.8.1. By Vector Type
- 13.8.2. By Type of Non-human Primates
- 13.8.3. By Application
- 13.8.4. By Therapeutic Area
- 13.8.5. By End-user
- 13.8.6. By Country

14. Asia Pacific Viral Vectors for Non-human Primates Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Vector Type, 2020-2034
- 14.2.1. Adenoviral Vectors
- 14.2.2. Adeno-associated Vectors
- 14.2.3. Retroviral Vectors
- 14.2.4. Lentiviral Vectors
- 14.2.5. Others
14.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
- 14.3.1. Marmosets
- 14.3.2. Rhesus macaques
- 14.3.3. Cynomolgus monkey
- 14.3.4. Others
14.4. Market Value Forecast By Application, 2020-2034
- 14.4.1. Gene Therapy
- 14.4.2. Vaccine Research
14.5. Market Value Forecast By Therapeutic Area, 2020-2034
- 14.5.1. Genetic Disorders
- 14.5.2. Infectious Diseases
- 14.5.3. Oncological Disorders
- 14.5.4. Others
14.6. Market Value Forecast By End-user, 2020-2034
- 14.6.1. Pharmaceutical and Biotechnology Companies
- 14.6.2. Academic and Research Institutions
14.7. Market Value Forecast By Country, 2020-2034
- 14.7.1. China
- 14.7.2. Japan
- 14.7.3. India
- 14.7.4. Australia & New Zealand
- 14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
- 14.8.1. By Vector Type
- 14.8.2. By Type of Non-human Primates
- 14.8.3. By Application
- 14.8.4. By Therapeutic Area
- 14.8.5. By End-user
- 14.8.6. By Country

15. Latin America Viral Vectors for Non-human Primates Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast By Vector Type, 2020-2034
- 15.2.1. Adenoviral Vectors
- 15.2.2. Adeno-associated Vectors
- 15.2.3. Retroviral Vectors
- 15.2.4. Lentiviral Vectors
- 15.2.5. Others
15.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
- 15.3.1. Marmosets
- 15.3.2. Rhesus macaques
- 15.3.3. Cynomolgus monkey
- 15.3.4. Others
15.4. Market Value Forecast By Application, 2020-2034
- 15.4.1. Gene Therapy
- 15.4.2. Vaccine Research
15.5. Market Value Forecast By Therapeutic Area, 2020-2034
- 15.5.1. Genetic Disorders
- 15.5.2. Infectious Diseases
- 15.5.3. Oncological Disorders
- 15.5.4. Others
15.6. Market Value Forecast By End-user, 2020-2034
- 15.6.1. Pharmaceutical and Biotechnology Companies
- 15.6.2. Academic and Research Institutions
15.7. Market Value Forecast By Country, 2020-2034
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
- 15.8.1. By Vector Type
- 15.8.2. By Type of Non-human Primates
- 15.8.3. By Application
- 15.8.4. By Therapeutic Area
- 15.8.5. By End-user
- 15.8.6. By Country

16. Middle East & Africa Viral Vectors for Non-human Primates Market Analysis and Forecast

16.1. Introduction
- 16.1.1. Key Findings
16.2. Market Value Forecast By Vector Type, 2020-2034
- 16.2.1. Adenoviral Vectors
- 16.2.2. Adeno-associated Vectors
- 16.2.3. Retroviral Vectors
- 16.2.4. Lentiviral Vectors
- 16.2.5. Others
16.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
- 16.3.1. Marmosets
- 16.3.2. Rhesus macaques
- 16.3.3. Cynomolgus monkey
- 16.3.4. Others
16.4. Market Value Forecast By Application, 2020-2034
- 16.4.1. Gene Therapy
- 16.4.2. Vaccine Research
16.5. Market Value Forecast By Therapeutic Area, 2020-2034
- 16.5.1. Genetic Disorders
- 16.5.2. Infectious Diseases
- 16.5.3. Oncological Disorders
- 16.5.4. Others
16.6. Market Value Forecast By End-user, 2020-2034
- 16.6.1. Pharmaceutical and Biotechnology Companies
- 16.6.2. Academic and Research Institutions
16.7. Market Value Forecast By Country, 2020-2034
- 16.7.1. GCC Countries
- 16.7.2. South Africa
- 16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
- 16.8.1. By Vector Type
- 16.8.2. By Type of Non-human Primates
- 16.8.3. By Application
- 16.8.4. By Therapeutic Area
- 16.8.5. By End-user
- 16.8.6. By Country

17. Competition Landscape

17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2023)
17.3. Market Footprint Analysis
- 17.3.1. By Region
- 17.3.2. By Vector Type
17.4. Competitive Snapshot
17.5. Company Profiles
- 17.5.1. Lonza
  - 17.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.1.2. Product Portfolio
  - 17.5.1.3. Financial Overview
  - 17.5.1.4. SWOT Analysis
  - 17.5.1.5. Strategic Overview
- 17.5.2. Thermo Fisher Scientific Inc
  - 17.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.2.2. Product Portfolio
  - 17.5.2.3. Financial Overview
  - 17.5.2.4. SWOT Analysis
  - 17.5.2.5. Strategic Overview
- 17.5.3. Revvity
  - 17.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.3.2. Product Portfolio
  - 17.5.3.3. Financial Overview
  - 17.5.3.4. SWOT Analysis
  - 17.5.3.5. Strategic Overview
- 17.5.4. VectorBuilder Inc.
  - 17.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.4.2. Product Portfolio
  - 17.5.4.3. Financial Overview
  - 17.5.4.4. SWOT Analysis
  - 17.5.4.5. Strategic Overview
- 17.5.5. Creative Biolabs
  - 17.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.5.2. Product Portfolio
  - 17.5.5.3. Financial Overview
  - 17.5.5.4. SWOT Analysis
  - 17.5.5.5. Strategic Overview
- 17.5.6. Takara Bio Inc
  - 17.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.6.2. Product Portfolio
  - 17.5.6.3. Financial Overview
  - 17.5.6.4. SWOT Analysis
  - 17.5.6.5. Strategic Overview
- 17.5.7. MERCK KGaA
  - 17.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.7.2. Product Portfolio
  - 17.5.7.3. Financial Overview
  - 17.5.7.4. SWOT Analysis
  - 17.5.7.5. Strategic Overview
- 17.5.8. Andelyn Biosciences
  - 17.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.8.2. Product Portfolio
  - 17.5.8.3. Financial Overview
  - 17.5.8.4. SWOT Analysis
  - 17.5.8.5. Strategic Overview
- 17.5.9. Biovian Oy
  - 17.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.9.2. Product Portfolio
  - 17.5.9.3. Financial Overview
  - 17.5.9.4. SWOT Analysis
  - 17.5.9.5. Strategic Overview
- 17.5.10. Genezen
  - 17.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.5.10.2. Product Portfolio
  - 17.5.10.3. Financial Overview
  - 17.5.10.4. SWOT Analysis
  - 17.5.10.5. Strategic Overview

한글목차

비인간 영장류용 바이러스 벡터 시장 - 조사 범위

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약: 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계 시장 분석과 예측 : 벡터 유형별

제7장 세계 시장 분석과 예측 : 비인간 영장류유형별

제8장 세계 시장 분석과 예측 : 용도별

제9장 세계 시장 분석과 예측 : 치료 영역별

제10장 세계 시장 분석과 예측 : 최종 사용자별

제11장 세계 시장 분석과 예측 : 지역별

제12장 북미 시장 분석과 예측

제13장 유럽 시장 분석과 예측

제14장 아시아태평양 시장 분석과 예측

제15장 라틴아메리카 시장 분석과 예측

제16장 중동 및 아프리카 시장 분석과 예측

제17장 경쟁 구도